MEP16408A - Combination of a taxane and a cyclin-dependent kinase inhibitor - Google Patents

Combination of a taxane and a cyclin-dependent kinase inhibitor

Info

Publication number
MEP16408A
MEP16408A MEP-164/08A MEP16408A MEP16408A ME P16408 A MEP16408 A ME P16408A ME P16408 A MEP16408 A ME P16408A ME P16408 A MEP16408 A ME P16408A
Authority
ME
Montenegro
Prior art keywords
cyclin
dependent kinase
taxane
combination
kinase inhibitor
Prior art date
Application number
MEP-164/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Marie-Christi Ne Bissery
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MEP16408A publication Critical patent/MEP16408A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-164/08A 2001-03-23 2002-03-22 Combination of a taxane and a cyclin-dependent kinase inhibitor MEP16408A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27794801P 2001-03-23 2001-03-23
US30269201P 2001-07-05 2001-07-05
US33491601P 2001-12-04 2001-12-04
PCT/EP2002/004083 WO2002076484A2 (en) 2001-03-23 2002-03-22 Combination of a taxane and a cyclin-dependent kinase inhibitor

Publications (1)

Publication Number Publication Date
MEP16408A true MEP16408A (en) 2010-10-10

Family

ID=27402954

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-164/08A MEP16408A (en) 2001-03-23 2002-03-22 Combination of a taxane and a cyclin-dependent kinase inhibitor

Country Status (33)

Country Link
US (2) US20020182204A1 (de)
EP (1) EP1372652B1 (de)
JP (1) JP2004521140A (de)
KR (1) KR100879712B1 (de)
CN (1) CN1498107A (de)
AR (1) AR034222A1 (de)
AT (1) ATE395917T1 (de)
AU (1) AU2002312815B2 (de)
BR (1) BR0208221A (de)
CA (1) CA2441441C (de)
CY (1) CY1110449T1 (de)
CZ (1) CZ301423B6 (de)
DE (1) DE60226710D1 (de)
DK (1) DK1372652T3 (de)
EA (1) EA007815B1 (de)
ES (1) ES2305253T3 (de)
HR (1) HRPK20030766B3 (de)
HU (1) HU229258B1 (de)
IL (2) IL158058A0 (de)
ME (1) MEP16408A (de)
MX (1) MXPA03007743A (de)
NO (1) NO332441B1 (de)
NZ (1) NZ527655A (de)
PE (1) PE20020907A1 (de)
PL (1) PL206118B1 (de)
PT (1) PT1372652E (de)
RS (1) RS50681B (de)
SI (1) SI1372652T1 (de)
SK (1) SK287481B6 (de)
TW (1) TWI355935B (de)
UY (1) UY27220A1 (de)
WO (1) WO2002076484A2 (de)
ZA (1) ZA200307381B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487434B1 (de) * 2002-03-06 2007-05-09 The Medical Research and Education Trust Botanischer extrakt mit antikrebs-aktivität enthaltend isoliquiritigenin
AU2003287081A1 (en) * 2002-10-16 2004-05-04 Ilex Products, Inc. Clofarabine and taxane chemotherapy combination
ES2318202T3 (es) * 2002-11-06 2009-05-01 Cyclacel Limited Combinacion que comprende docetaxel y un inhibidor de cdk.
JP5537035B2 (ja) * 2006-02-10 2014-07-02 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｃｄｋ阻害剤、および成長因子抗体または抗有糸***剤を含む組合せ
CN104220066A (zh) * 2010-11-19 2014-12-17 皮拉马尔企业有限公司 紫杉醇和cdk抑制剂药物组合物
PL2694056T3 (pl) * 2011-04-01 2020-03-31 Astrazeneca Ab Leczenie terapeutyczne
MY175800A (en) 2011-11-30 2020-07-09 Astrazeneca Ab Combination treatment of cancer
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
AU2195297A (en) * 1996-02-20 1997-09-02 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers

Also Published As

Publication number Publication date
AU2002312815B2 (en) 2006-08-24
PL367702A1 (en) 2005-03-07
US20020182204A1 (en) 2002-12-05
PL206118B1 (pl) 2010-07-30
IL158058A (en) 2010-02-17
MXPA03007743A (es) 2004-11-12
NZ527655A (en) 2006-03-31
CA2441441A1 (en) 2002-10-03
US20060128640A1 (en) 2006-06-15
BR0208221A (pt) 2004-03-02
EA007815B1 (ru) 2007-02-27
NO20034124D0 (no) 2003-09-16
PT1372652E (pt) 2008-07-24
HU229258B1 (en) 2013-10-28
TWI355935B (en) 2012-01-11
WO2002076484A3 (en) 2003-01-03
KR100879712B1 (ko) 2009-01-22
JP2004521140A (ja) 2004-07-15
KR20030086318A (ko) 2003-11-07
CA2441441C (en) 2009-05-26
HRP20030766A2 (en) 2005-06-30
CY1110449T1 (el) 2015-04-29
IL158058A0 (en) 2004-03-28
DK1372652T3 (da) 2008-09-22
NO332441B1 (no) 2012-09-17
ES2305253T3 (es) 2008-11-01
CZ301423B6 (cs) 2010-02-24
CZ20032551A3 (en) 2004-07-14
PE20020907A1 (es) 2002-12-19
EA200301053A1 (ru) 2004-02-26
ZA200307381B (en) 2005-03-30
CN1498107A (zh) 2004-05-19
YU69503A (sh) 2006-08-17
HRPK20030766B3 (en) 2006-11-30
SK287481B6 (sk) 2010-11-08
ATE395917T1 (de) 2008-06-15
SK11692003A3 (sk) 2004-03-02
EP1372652A2 (de) 2004-01-02
EP1372652B1 (de) 2008-05-21
AR034222A1 (es) 2004-02-04
UY27220A1 (es) 2002-09-30
SI1372652T1 (sl) 2008-10-31
RS50681B (sr) 2010-06-30
HUP0303589A2 (hu) 2004-03-01
WO2002076484A2 (en) 2002-10-03
NO20034124L (no) 2003-09-16
HUP0303589A3 (en) 2007-05-02
DE60226710D1 (de) 2008-07-03

Similar Documents

Publication Publication Date Title
HN2002000300A (es) Nuevos derivados de piperazina
CR8824A (es) Derivados de 2-carbamida-4-feniltiazol, su preparacion y su aplicacion en terapeutica
EE05081B1 (et) Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, 3-aminoasetidiini derivaadid ja nende valmistamise meetodid
BR0215184A (pt) composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada
BRPI0108395B8 (pt) derivados de pirrolopirimidinona, processos de preparação e uso
AR063555A1 (es) Derivados de androstano, su uso en la fabricacion de medicamentos, composiciones farmaceuticas que los comprenden y procesos para prepararlos
PA8539901A1 (es) Novedosa sal de succinato de o-desmetil-venlafaxina
CY1108522T1 (el) Μεθοδος συνθεσης της περινδοπριλης και των φαρμακευτικως αποδεκτων αλατων της
AR030857A1 (es) Derivados nitroso de difenolaminas, composiciones farmaceuticas que los contienen y su uso en la preparacion de productos medicinales
CY1110258T1 (el) Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
CY1110449T1 (el) Συνδυασμος δοκεταξελης και φλαβοπιριδinολης
BRPI0415053B8 (pt) inibidor de glicoproteína-p, método para preparar o mesmo e composição farmacêutica que compreende o mesmo
HN2001000235A (es) Derivados puentes de piperazina
AR029509A1 (es) Una composicion farmaceutica en base a un compuesto de platino (iv) y el uso de dicho compuesto para preparar medicamentos antitumorales
BR0208566B1 (pt) Derivados de Beta-Carbolina, Seu Uso, e composição Farmacêutica
ITRM20030363A1 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
CY1106712T1 (el) Υποκατεστημενα παραγωγα 5-αμινο-1-πεντεν-3-ολης
UY27133A1 (es) 11beta-halogenesteroides, su obtención y uso para la preparación de medicamentos y preparados farmacéuticos que contienen 11 beta-halogenesteroides
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
HN2001000021A (es) Nuevos derivados de amidas heterociclicas
AR029091A1 (es) Uso de compuestos de 1-amino-5-fenilpentano-3-ol y/o 1-amino-6-fenilhexano-3-ol para la preparacion de un medicamento con efecto antagonista de n-metil-d-aspartato-(nmda)
UY27376A1 (es) Formulación de medicamento que contiene un antagonista de ltb4
ATE301469T1 (de) Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase
FR2797446B1 (fr) Derives de phenanthroline-7-ones et leurs applications en therapeutique